查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1675376

微小殘留疾病檢測市場按技術（流式細胞儀、聚合酶鍊式反應、下一代定序等）、應用、最終用戶和地區分類，2025 年至 2033 年

Minimal Residual Disease Testing Market by Technology (Flow Cytometry, Polymerase Chain Reaction, Next Generation Sequencing, and Others), Application, End User, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 138 Pages | 商品交期: 2-3個工作天內

價格

2024 年全球微小殘留疾病 ( IMARC Group ) 檢測市場規模達到 23 億美元。醫療保健產業的顯著成長、廣泛的研究和開發 (R&D) 活動和快速的技術進步是推動市場發展的一些關鍵因素。

微小殘留疾病（MRD）檢測是一種醫學檢測，用於檢測和監測患者接受癌症治療後可能殘留在體內的少量癌細胞。它被廣泛用於檢測多種不同類型的癌症，例如白血病、淋巴瘤、多發性骨髓瘤和一些實體腫瘤。 MRD 檢測使用高度敏感的方法，包括流式細胞儀、聚合酶鏈反應 (PCR) 和次世代定序 (NGS)。它是監測癌症患者並幫助醫生做出更明智治療決策的重要醫學測試。 MRD 檢測有助於早期發現疾病復發，提供更準確的治療反應評估，並透過識別患者、改善患者結果和加強客製化治療計劃來指導個人化治療計劃。

微小殘留疾病 (MRD) 檢測市場趨勢：

全球癌症發生率的上升是推動市場成長的關鍵因素之一。 MRD 檢測是一種高度敏感的技術，廣泛用於檢測殘留癌細胞，有助於早期發現疾病復發並有助於指導個人化治療計劃。與此一致，MRD 測試被廣泛採用作為始於造血組織或免疫系統細胞的血液系統癌症的診斷和監測工具，有利於市場的成長。此外，消費者對允許客製化治療計劃和監測的個人化醫療的偏好轉變也是另一個促進成長的因素。除此之外，人工智慧 (AI) 與 MRD 測試的結合有助於識別模式、預測復發的可能性、提高診斷的準確性和有效性，並幫助臨床醫生就患者護理做出更明智的決策，從而為市場成長提供了動力。此外，擴大採用NGS技術來確定脫氧核糖核酸（DNA）或核糖核酸（RNA）的序列以研究與疾病相關的遺傳變異，為市場創造了積極的前景。此外，人們越來越意識到識別體內是否存在可能導致癌症的致癌物質的重要性，這推動了市場的成長。其他因素，包括醫療保健行業的顯著成長、廣泛的研究和開發 (R&D) 活動以及對 MRD 測試項目領域的投資增加，預計將推動市場成長。

本報告回答的關鍵問題：

  • 全球微小殘留疾病（MRD）檢測市場迄今表現如何，未來幾年將如何表現？
  • 全球微小殘留疾病 (MRD) 檢測市場的促進因素、限制因素和機會有哪些？
  • 每個促進因素、限制因素和機會對全球微小殘留疾病 (MRD) 檢測市場有何影響？
  • 主要的區域市場有哪些？
  • 哪些國家擁有最具吸引力的微小殘留疾病 (MRD) 檢測市場？
  • 基於科技的市場分化是怎樣的？
  • 微小殘留疾病（MRD）檢測市場中哪種技術最具吸引力？
  • 根據應用，市場區隔是怎樣的？
  • 微小殘留疾病（MRD）檢測市場中最具吸引力的應用是什麼？
  • 根據最終用戶，市場分佈如何？
  • 微小殘留疾病（MRD）檢測市場中最具吸引力的最終用戶是誰？
  • 全球微小殘留疾病（MRD）檢測市場的競爭結構如何？
  • 全球微小殘留疾病 (MRD) 檢測市場的關鍵參與者/公司有哪些？

目錄

第 1 章：前言

第 2 章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球微小殘留疾病 (MRD) 檢測市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場預測

第6章：市場區隔：依技術

  • 流式細胞儀
  • 聚合酶鍊式反應（PCR）
  • 下一代定序（NGS）
  • 其他

第7章：市場區隔：依應用

  • 血液系統惡性腫瘤
    • 關鍵部分
      • 白血病
      • 淋巴瘤
  • 實體腫瘤

第 8 章：市場區隔：依最終用戶

  • 醫院和專科診所
  • 診斷實驗室
  • 學術及研究機構
  • 其他

第9章：市場細分：依地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場區隔：依國家

第 10 章：促進因素、限制因素與機遇

  • 概述
  • 驅動程式
  • 限制
  • 機會

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第 14 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Adaptive Biotechnologies Corporation
    • Arup Laboratories Inc.
    • Bio-Rad Laboratories Inc.
    • Guardant Health
    • Invivoscribe Inc.
    • Natera Inc.
    • NeoGenomics Laboratories Inc.
    • Sysmex Corporation
Product Code: SR112025A7248

The global minimal residual disease (MRD) testing market size reached USD 2.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.5 Billion by 2033, exhibiting a growth rate (CAGR) of 9.7% during 2025-2033. Significant growth in the healthcare industry, extensive research and development (R&D) activities and rapid technological advancements represent some of the key factors driving the market.

Minimal residual disease (MRD) testing is a medical test used to detect and monitor small amounts of cancer cells that may remain in a patient's body after undergoing cancer treatment. It is widely used to test a variety of different types of cancer, such as leukemia, lymphoma, multiple myeloma, and some solid tumors. MRD testing uses highly sensitive methods, including cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS). It is an important medical test for monitoring cancer patients and helping doctors to make more informed treatment decisions. MRD testing helps in the early detection of disease recurrence, providing a more accurate assessment of treatment response and guiding personalized treatment planning by identifying patients, improving patient outcomes, and enhancing customized treatment planning.

Minimal Residual Disease (MRD) Testing Market Trends:

The increasing prevalence of cancer across the globe is one of the key factors driving the market growth. MRD testing is a highly sensitive technique that is widely used to detect residual cancer cells, which helps in an early indication of disease recurrence and helps guide personalized treatment planning. In line with this, the widespread adoption of MRD testing as a diagnostic and monitoring tool in hematological cancers that begin in blood-forming tissues or the cell of the immune system is favoring the market growth. Moreover, the shifting consumer preference toward personalized medicine that allows customized treatment planning and monitoring are acting as another growth-inducing factor. Apart from this, the integration of artificial intelligence (AI) with MRD testing that helps to identify patterns, predict the likelihood of recurrence, improve the accuracy and effectiveness of diagnosis, and help clinicians to make more informed decisions about patient care, is providing an impetus to the market growth. Additionally, the increasing adoption of NGS technology to determine the sequence of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) to study the genetic variations associated with the disease is creating a positive outlook for the market. Furthermore, growing awareness among people about the importance of identifying the presence of carcinogenic substances that can cause cancer in the body is propelling the market growth. Other factors, including significant growth in the healthcare industry, extensive research and development (R&D) activities, and increasing investments in the field of MRD testing programs, are anticipated to drive the market growth.

Key Market Segmentation:

Technology Insights:

  • Flow Cytometry
  • Polymerase Chain Reaction (PCR)
  • Next Generation Sequencing (NGS)
  • Others

Application Insights:

  • Hematological Malignancy
  • Leukemia
  • Lymphoma
  • Solid Tumors

End User Insights:

  • Hospitals and Speciality Clinics
  • Diagnostic Laboratories
  • Academic and Research Institutes
  • Others

Regional Insights:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for minimal residual disease (MRD) testing. Some of the factors driving the North America minimal residual disease (MRD) testing market included the increasing prevalence of cancer, significant growth in the healthcare industry, and extensive research and development (R&D) activities.

Competitive Landscape:

  • The report has also provided a comprehensive analysis of the competitive landscape in the global minimal residual disease (MRD) testing market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Adaptive Biotechnologies Corporation, Arup Laboratories Inc., Bio-Rad Laboratories Inc., Guardant Health, Invivoscribe Inc., Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, etc.

Key Questions Answered in This Report:

  • How has the global minimal residual disease (MRD) testing market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global minimal residual disease (MRD) testing market?
  • What is the impact of each driver, restraint, and opportunity on the global minimal residual disease (MRD) testing market?
  • What are the key regional markets?
  • Which countries represent the most attractive minimal residual disease (MRD) testing market?
  • What is the breakup of the market based on technology?
  • Which is the most attractive technology in the minimal residual disease (MRD) testing market?
  • What is the breakup of the market based on the application?
  • Which is the most attractive application in the minimal residual disease (MRD) testing market?
  • What is the breakup of the market based on the end user?
  • Which is the most attractive end user in the minimal residual disease (MRD) testing market?
  • What is the competitive structure of the global minimal residual disease (MRD) testing market?
  • Who are the key players/companies in the global minimal residual disease (MRD) testing market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Minimal Residual Disease (MRD) Testing Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Technology

  • 6.1 Flow Cytometry
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Polymerase Chain Reaction (PCR)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Next Generation Sequencing (NGS)
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Hematological Malignancy
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Leukemia
      • 7.1.2.2 Lymphoma
    • 7.1.3 Market Forecast
  • 7.2 Solid Tumors
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals and Speciality Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Diagnostic Laboratories
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Academic and Research Institutes
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Adaptive Biotechnologies Corporation
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Arup Laboratories Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 SWOT Analysis
    • 14.3.3 Bio-Rad Laboratories Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Guardant Health
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Invivoscribe Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Natera Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 NeoGenomics Laboratories Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
    • 14.3.8 Sysmex Corporation
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

  • Figure 1: Global: Minimal Residual Disease Testing Market: Major Drivers and Challenges
  • Figure 2: Global: Minimal Residual Disease Testing Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Minimal Residual Disease Testing Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Minimal Residual Disease Testing Market: Breakup by Technology (in %), 2024
  • Figure 5: Global: Minimal Residual Disease Testing Market: Breakup by Application (in %), 2024
  • Figure 6: Global: Minimal Residual Disease Testing Market: Breakup by End User (in %), 2024
  • Figure 7: Global: Minimal Residual Disease Testing Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Minimal Residual Disease Testing (Flow Cytometry) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Minimal Residual Disease Testing (Flow Cytometry) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Minimal Residual Disease Testing (Polymerase Chain Reaction (PCR)) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Minimal Residual Disease Testing (Polymerase Chain Reaction (PCR)) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Minimal Residual Disease Testing (Next Generation Sequencing (NGS)) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Minimal Residual Disease Testing (Next Generation Sequencing (NGS)) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Minimal Residual Disease Testing (Other Technologies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Minimal Residual Disease Testing (Other Technologies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Minimal Residual Disease Testing (Hematological Malignancy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Minimal Residual Disease Testing (Hematological Malignancy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Minimal Residual Disease Testing (Solid Tumors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Minimal Residual Disease Testing (Solid Tumors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Minimal Residual Disease Testing (Hospitals and Speciality Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Minimal Residual Disease Testing (Hospitals and Speciality Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Minimal Residual Disease Testing (Diagnostic Laboratories) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Minimal Residual Disease Testing (Diagnostic Laboratories) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Minimal Residual Disease Testing (Academic and Research Institutes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Minimal Residual Disease Testing (Academic and Research Institutes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Minimal Residual Disease Testing (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Minimal Residual Disease Testing (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: North America: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: North America: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: United States: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: United States: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Canada: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Canada: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Asia-Pacific: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Asia-Pacific: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: China: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: China: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Japan: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Japan: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: India: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: India: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: South Korea: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: South Korea: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Australia: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Australia: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Indonesia: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Indonesia: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Others: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Others: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Europe: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Europe: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Germany: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Germany: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: France: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: France: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: United Kingdom: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: United Kingdom: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Italy: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Italy: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Spain: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Spain: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Russia: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Russia: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Others: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Others: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Latin America: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Latin America: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Brazil: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Brazil: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Mexico: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Mexico: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Others: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Others: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Middle East and Africa: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Middle East and Africa: Minimal Residual Disease Testing Market: Breakup by Country (in %), 2024
  • Figure 76: Middle East and Africa: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Global: Minimal Residual Disease Testing Industry: Drivers, Restraints, and Opportunities
  • Figure 78: Global: Minimal Residual Disease Testing Industry: Value Chain Analysis
  • Figure 79: Global: Minimal Residual Disease Testing Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Minimal Residual Disease Testing Market: Key Industry Highlights, 2024 & 2033
  • Table 2: Global: Minimal Residual Disease Testing Market Forecast: Breakup by Technology (in Million USD), 2025-2033
  • Table 3: Global: Minimal Residual Disease Testing Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 4: Global: Minimal Residual Disease Testing Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 5: Global: Minimal Residual Disease Testing Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Minimal Residual Disease Testing Market: Competitive Structure
  • Table 7: Global: Minimal Residual Disease Testing Market: Key Players